Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92337C203 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Armistice Capital, LLC
13G/A
Amendment 2
|
7.8% |
8/14/2026
Event 6/30/2026
|
|
| Armistice Capital, LLC | 7.8% | ||
| Steven Boyd | 7.8% | ||
| State Street Corp 13G | 5.8% |
8/7/2026
Event 6/30/2026
|
|
| Vanguard Capital Management LLC 13G | 5.0% |
7/31/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 7.0% |
7/30/2026
Event 6/30/2026
|
|
|
Polar Capital Holdings Plc
13G/A
Amendment 1
|
4.8% |
7/8/2026
Event 3/31/2026
|
|
| Polar Capital Holdings Plc | 4.8% | ||
| Polar Capital LLP | 4.8% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 4.8% | ||
|
RTW Investments, LP
13G/A
Amendment 3
|
9.9% |
5/15/2026
Event 3/31/2026
|
|
| RTW Investments, LP | 9.9% | ||
| Roderick Wong | 9.9% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 5
|
1.6% |
5/15/2026
Event 3/31/2026
|
|
| Balyasny Asset Management L.P. | 1.6% | ||
| Bam GP LLC | 1.6% | ||
| Balyasny Asset Management Holdings LP | 1.6% | ||
| Dames GP LLC | 1.6% | ||
| Dmitry Balyasny | 1.6% | ||
|
Armistice Capital, LLC
13G/A
Amendment 1
|
5.2% |
5/15/2026
Event 3/31/2026
|
|
| Armistice Capital, LLC | 5.2% | ||
| Steven Boyd | 5.2% | ||
|
Foresite Capital Fund VI LP
13G/A
Amendment 1
|
3.6% |
5/15/2026
Event 3/31/2026
|
|
| Foresite Capital Fund VI LP | 3.6% | ||
| Foresite Capital Management VI LLC | 3.6% | ||
| Tananbaum James B. | 3.6% | ||
| Vanguard Group Inc 13G/A Amendment 2 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
RTW Investments, LP
13G/A
Amendment 2
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| RTW Investments, LP | 9.9% | ||
| Roderick Wong | 9.9% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 4
|
6.2% |
2/17/2026
Event 12/31/2025
|
|
| Balyasny Asset Management L.P. | 6.2% | ||
| Bam GP LLC | 6.2% | ||
| Balyasny Asset Management Holdings LP | 6.2% | ||
| Dames GP LLC | 6.2% | ||
| Dmitry Balyasny | 6.2% | ||
|
Armistice Capital, LLC
13G
|
5.3% |
2/17/2026
Event 12/31/2025
|
|
| Armistice Capital, LLC | 5.3% | ||
| Steven Boyd | 5.3% | ||
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
1.3% |
2/17/2026
Event 12/31/2025
|
|
| Point72 Asset Management, L.P. | 1.3% | ||
| Point72 Capital Advisors, Inc. | 1.3% | ||
| Steven A. Cohen | 1.3% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 4
|
4.7% |
2/13/2026
Event 12/31/2025
|
|
| Nantahala Capital Management, LLC | 4.7% | ||
| Wilmot B. Harkey | 4.7% | ||
| Daniel Mack | 4.7% | ||
|
Polar Capital Holdings Plc
13G
|
5.1% |
1/5/2026
Event 12/31/2025
|
|
| Polar Capital Holdings Plc | 5.1% | ||
| Polar Capital LLP | 5.1% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 5.1% | ||
|
Deep Track Capital, LP
13G
|
10.0% |
11/21/2025
Event 11/14/2025
|
|
| Deep Track Capital, LP | 10.0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 10.0% | ||
| David Kroin | 10.0% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 3
|
9.3% |
11/14/2025
Event 9/30/2025
|
|
| Balyasny Asset Management L.P. | 9.3% | ||
| Bam GP LLC | 9.3% | ||
| Balyasny Asset Management Holdings LP | 9.3% | ||
| Dames GP LLC | 9.3% | ||
| Dmitry Balyasny | 9.3% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 3
|
7.1% |
11/14/2025
Event 9/30/2025
|
|
| Nantahala Capital Management, LLC | 7.1% | ||
| Wilmot B. Harkey | 7.1% | ||
| Daniel Mack | 7.1% | ||
|
Logos Global Management LP
13G/A
Amendment 1
|
4.8% |
11/14/2025
Event 9/30/2025
|
|
| Logos Global Management LP | 4.8% | ||
| Logos Global Management GP LLC | 4.8% | ||
| Logos Global Master Fund LP | 4.8% | ||
| Logos GP LLC | 4.8% | ||
| Arsani William | 4.8% | ||
|
Stonepine Capital Management, LLC
13G/A
Amendment 1
|
4.3% |
11/13/2025
Event 9/30/2025
|
|
| Stonepine Capital Management, LLC | 4.3% | ||
| Stonepine Capital, L.P. | 4.3% | ||
| Stonepine GP, LLC | 4.3% | ||
| Jon M. Plexico | 4.3% | ||
|
Foresite Capital Fund VI LP
13G
|
5.1% |
10/23/2025
Event 10/16/2025
|
|
| Foresite Capital Fund VI LP | 5.1% | ||
| Foresite Capital Management VI, LLC | 5.1% | ||
| Tananbaum James B. | 5.1% | ||
| BlackRock, Inc. 13G | 6.0% |
10/17/2025
Event 9/30/2025
|
|
|
RTW Investments, LP
13G/A
Amendment 1
|
9.9% |
8/14/2025
Event 6/30/2025
|
|
| RTW Investments, LP | 9.9% | ||
| Roderick Wong | 9.9% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 2
|
10.0% |
8/14/2025
Event 6/30/2025
|
|
| Balyasny Asset Management L.P. | 10.0% | ||
| Bam GP LLC | 10.0% | ||
| Balyasny Asset Management Holdings LP | 10.0% | ||
| Dames GP LLC | 10.0% | ||
| Dmitry Balyasny | 10.0% | ||
| Orbimed Advisors LLC 13G/A Amendment 4 | 2.4% |
8/14/2025
Event 6/30/2025
|
|
|
Biotechnology Value Fund L P
13G/A
Amendment 10
|
3.9% |
8/13/2025
Event 8/11/2025
|
|
| Biotechnology Value Fund L P | 2.2% | ||
| BVF I GP LLC | 2.2% | ||
| Biotechnology Value Fund II LP | 1.5% | ||
| BVF II GP LLC | 1.5% | ||
| Biotechnology Value Trading Fund OS LP | 0.2% | ||
| BVF Partners OS Ltd. | 0.2% | ||
| BVF GP Holdings LLC | 3.6% | ||
| BVF Partners L P/IL | 3.9% | ||
| BVF Inc/IL | 3.9% | ||
| Lampert Mark N | 3.9% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 9
|
10.0% |
8/13/2025
Event 6/30/2025
|
|
| Biotechnology Value Fund L P | 5.8% | ||
| BVF I GP LLC | 5.8% | ||
| Biotechnology Value Fund II LP | 3.9% | ||
| BVF II GP LLC | 3.9% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 9.5% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
| Barclays PLC 13G/A Amendment 2 |
Checked 5% or less
|
8/12/2025
Event 6/30/2025
|
|
|
Stonepine Capital Management, LLC
13G
|
5.0% |
8/6/2025
Event 7/22/2025
|
|
| Stonepine Capital Management, LLC | 5.0% | ||
| Stonepine Capital, L.P. | 5.0% | ||
| Stonepine GP, LLC | 5.0% | ||
| Jon M. Plexico | 5.0% | ||
|
Orin Hirschman
13G/A
Amendment 1
|
3.6% |
7/29/2025
Event 6/30/2025
|
|
| Orin Hirschman | 3.6% | ||
| AIGH Capital Management LLC | 3.6% | ||
| Vanguard Group Inc 13G | 6.2% |
7/29/2025
Event 6/30/2025
|
|
|
Logos Global Management LP
13G
|
6.2% |
7/28/2025
Event 7/21/2025
|
|
| Logos Global Management LP | 6.2% | ||
| Logos Global Management GP LLC | 6.2% | ||
| Logos Global Master Fund LP | 6.2% | ||
| Logos GP LLC | 6.2% | ||
| Arsani William | 6.2% | ||
|
Point72 Asset Management, L.P.
13G
|
6.1% |
7/28/2025
Event 7/25/2025
|
|
| Point72 Asset Management, L.P. | 6.1% | ||
| Point72 Capital Advisors, Inc. | 6.1% | ||
| Steven A. Cohen | 6.1% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 2
|
10.0% |
5/15/2025
Event 3/31/2025
|
|
| Nantahala Capital Management, LLC | 10.0% | ||
| Wilmot B. Harkey | 10.0% | ||
| Daniel Mack | 10.0% | ||
|
RTW Investments, LP
13G
|
8.3% |
5/15/2025
Event 3/31/2025
|
|
| RTW Investments, LP | 8.3% | ||
| Roderick Wong, M.D. | 8.3% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 1
|
9.3% |
5/15/2025
Event 3/31/2025
|
|
| Balyasny Asset Management L.P. | 9.3% | ||
| Bam GP LLC | 9.3% | ||
| Balyasny Asset Management Holdings LP | 9.3% | ||
| Dames GP LLC | 9.3% | ||
| Dmitry Balyasny | 9.3% | ||
| OrbiMed Advisors LLC 13G/A Amendment 3 | 5.6% |
5/15/2025
Event 3/31/2025
|
|
|
Soleus Private Equity Fund III, L.P.
13G/A
Amendment 4
|
1.8% |
5/2/2025
Event 3/31/2025
|
|
| Soleus Private Equity Fund III, L.P. | 0.7% | ||
| Soleus Private Equity GP III, LLC | 0.7% | ||
| Soleus PE GP III, LLC | 0.7% | ||
| Soleus Capital Master Fund, L.P. | 1.2% | ||
| Soleus Capital, LLC | 1.2% | ||
| Soleus Capital Group, LLC | 1.2% | ||
| Soleus Capital Management, L.P. | 1.8% | ||
| Soleus GP, LLC | 1.8% | ||
| Guy Levy | 1.8% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 4.7% |
4/30/2025
Event 3/31/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 4.9% |
4/24/2025
Event 3/31/2025
|
|
| Barclays PLC 13G/A Amendment 1 | 8.9% |
3/21/2025
Event 12/31/2024
|
|
|
Alyeska Investment Group, L.P.
13G/A
Amendment 1
|
2.1% |
2/14/2025
Event 12/31/2024
|
|
| Alyeska Investment Group, L.P. | 2.1% | ||
| Alyeska Fund GP, LLC | 2.1% | ||
| Anand Parekh | 2.1% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
10.0% |
2/14/2025
Event 12/31/2024
|
|
| Nantahala Capital Management, LLC | 10.0% | ||
| Wilmot B. Harkey | 10.0% | ||
| Daniel Mack | 10.0% | ||
|
Balyasny Asset Management L.P.
13G
|
8.9% |
2/14/2025
Event 12/31/2024
|
|
| Balyasny Asset Management L.P. | 8.9% | ||
| Bam GP LLC | 8.9% | ||
| Balyasny Asset Management Holdings LP | 8.9% | ||
| Dames GP LLC | 8.9% | ||
| Dmitry Balyasny | 8.9% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 8
|
10.0% |
2/14/2025
Event 12/31/2024
|
|
| Biotechnology Value Fund L P | 6.0% | ||
| BVF I GP LLC | 6.0% | ||
| Biotechnology Value Fund II LP | 3.8% | ||
| BVF II GP LLC | 3.8% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 9.5% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
| Barclays PLC 13G | 8.9% |
2/14/2025
Event 12/31/2024
|
|
|
Stonepine Capital Management, LLC
13G/A
Amendment 2
|
4.8% |
2/13/2025
Event 12/31/2024
|
|
| Stonepine Capital Management, LLC | 4.8% | ||
| Stonepine Capital, L.P. | 4.8% | ||
| Stonepine GP, LLC | 4.8% | ||
| Jon M. Plexico | 4.8% | ||
|
Soleus Capital Master Fund, L.P.
13G/A
Amendment 3
|
7.3% |
2/11/2025
Event 12/31/2024
|
|
| Soleus Private Equity Fund III, L.P. | 3.9% | ||
| Soleus Private Equity GP III, LLC | 3.9% | ||
| Soleus PE GP III, LLC | 3.9% | ||
| Soleus Capital Master Fund, L.P. | 3.5% | ||
| Soleus Capital, LLC | 3.5% | ||
| Soleus Capital Group, LLC | 3.5% | ||
| Soleus Capital Management, L.P. | 7.3% | ||
| Soleus GP LLC | 7.3% | ||
| Guy Levy | 7.3% | ||
| Vanguard Group Inc 13G | 5.2% |
1/31/2025
Event 12/31/2024
|
|
|
Orin Hirschman
13G
|
6.1% |
1/21/2025
Event 12/31/2024
|
|
| Orin Hirschman | 6.1% | ||
| AIGH Capital Management LLC | 6.1% | ||
|
Nantahala Capital Management, LLC
13G
|
10.0% |
11/14/2024
Event 9/30/2024
|
|
| Nantahala Capital Management, LLC | 10.0% | ||
| Wilmot B. Harkey | 10.0% | ||
| Daniel Mack | 10.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 1.16 k | $9.31 k |
| 2026 Q2 | 169 | 98.9 M | $379 M |
| 2026 Q1 | 163 | 81.4 M | $432 M |
| 2025 Q4 | 151 | 76.5 M | $591 M |
| 2025 Q3 | 126 | 59.6 M | $527 M |
| 2025 Q2 | 119 | 53.0 M | $220 M |
| 2025 Q1 | 105 | 43.3 M | $261 M |
| 2024 Q4 | 95 | 35.4 M | $181 M |
| 2024 Q3 | 82 | 26.6 M | $80.4 M |
| 2024 Q2 | 75 | 15.2 M | $45.2 M |
| 2024 Q1 | 77 | 17.0 M | $201 M |
| 2023 Q4 | 63 | 16.8 M | $137 M |
| 2023 Q3 | 60 | 16.8 M | $136 M |
| 2023 Q2 | 64 | 16.1 M | $120 M |